96 related articles for article (PubMed ID: 22765651)
1. Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?
Norman P
Expert Opin Ther Pat; 2012 Aug; 22(8):965-70. PubMed ID: 22765651
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal.
Norman P
Expert Opin Ther Pat; 2012 Aug; 22(8):971-6. PubMed ID: 22768915
[TBL] [Abstract][Full Text] [Related]
3. Aryl amide derivatives of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives useful as ASK1 inhibitors, an evaluation of WO2012080735.
Norman P
Expert Opin Ther Pat; 2012 Dec; 22(12):1479-83. PubMed ID: 22917158
[TBL] [Abstract][Full Text] [Related]
4. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
Begg M; Edwards CD; Hamblin JN; Pefani E; Wilson R; Gilbert J; Vitulli G; Mallett D; Morrell J; Hingle MI; Uddin S; Ehtesham F; Marotti M; Harrell A; Newman CF; Fernando D; Clark J; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):443-453. PubMed ID: 30940692
[TBL] [Abstract][Full Text] [Related]
5. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Zhu J; Hou T; Mao X
Drug Discov Today; 2015 Aug; 20(8):988-94. PubMed ID: 25857437
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation.
Ellard K; Sunose M; Bell K; Ramsden N; Bergamini G; Neubauer G
Bioorg Med Chem Lett; 2012 Jul; 22(14):4546-9. PubMed ID: 22738635
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of WO2012003387, Gilead's ASK1 inhibitors.
Norman P
Expert Opin Ther Pat; 2012 Apr; 22(4):455-9. PubMed ID: 22439661
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
Norman P
Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729.
Norman P
Expert Opin Ther Pat; 2014 Apr; 24(4):471-5. PubMed ID: 24283201
[TBL] [Abstract][Full Text] [Related]
10. Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor.
Ryu BJ; Kim S; Min B; Kim KY; Lee JS; Park WJ; Lee H; Kim SH; Park S
Cancer Lett; 2014 Jul; 349(1):45-50. PubMed ID: 24704155
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.
Wagner J; von Matt P; Sedrani R; Albert R; Cooke N; Ehrhardt C; Geiser M; Rummel G; Stark W; Strauss A; Cowan-Jacob SW; Beerli C; Weckbecker G; Evenou JP; Zenke G; Cottens S
J Med Chem; 2009 Oct; 52(20):6193-6. PubMed ID: 19827831
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.
Norman P
Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077
[TBL] [Abstract][Full Text] [Related]
13. BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857.
Norman P
Expert Opin Ther Pat; 2009 Aug; 19(8):1165-8. PubMed ID: 19505194
[TBL] [Abstract][Full Text] [Related]
14. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
[TBL] [Abstract][Full Text] [Related]
15. First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors.
Niu C; Boschelli DH; Tumey LN; Bhagirath N; Subrath J; Shim J; Wang Y; Wu B; Eid C; Lee J; Yang X; Brennan A; Chaudhary D
Bioorg Med Chem Lett; 2009 Oct; 19(20):5829-32. PubMed ID: 19762237
[TBL] [Abstract][Full Text] [Related]
16. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors.
Gentile G; Merlo G; Pozzan A; Bernasconi G; Bax B; Bamborough P; Bridges A; Carter P; Neu M; Yao G; Brough C; Cutler G; Coffin A; Belyanskaya S
Bioorg Med Chem Lett; 2012 Mar; 22(5):1989-94. PubMed ID: 22310227
[TBL] [Abstract][Full Text] [Related]
17. N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors.
Xu YJ; Miao HQ; Pan W; Navarro EC; Tonra JR; Mitelman S; Camara MM; Deevi DS; Kiselyov AS; Kussie P; Wong WC; Liu H
Bioorg Med Chem Lett; 2006 Jan; 16(2):404-8. PubMed ID: 16246551
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
Medina M; Castro A
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):533-43. PubMed ID: 18600569
[TBL] [Abstract][Full Text] [Related]
19. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
